The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
O'Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, Lu H, Xu L, Wendland JR, Dunayevich E, Buhl DL, Litman R, Hetrick WP, Hong LE, Rosen LB.
O'Donnell P, et al. Among authors: hetrick wp.
Neuropsychopharmacology. 2023 Jun;48(7):1052-1059. doi: 10.1038/s41386-023-01560-0. Epub 2023 Mar 16.
Neuropsychopharmacology. 2023.
PMID: 36928351
Free PMC article.
Clinical Trial.